• Bionote posted a third-quarter 2026 net loss of KRW 65.34 billion, reversing a year-earlier profit of KRW 17.94 billion.
• Revenue rose 8.7% year over year to KRW 32.07 billion.
• Operating profit increased 65.6% from a year earlier to KRW 7.99 billion.
• Sequentially, revenue fell 11.8%, while operating profit declined 5.5%.
• Nine-month net loss totaled KRW 14.96 billion, versus a profit of KRW 106.5 billion a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bionote Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261112800369), on November 12, 2026, and is solely responsible for the information contained therein.